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MATERNAL ANTIBODIES IN AUTISM:  
WHAT IS KNOWN AND FUTURE DIRECTIONS  
 ANISHA BHANOT 
ABSTRACT 
 Autism spectrum disorder (ASD) refers to a highly prevalent neuropsychiatric 
disorder, currently affecting one in every 68 children. ASD is understood as a 
heterogeneous disorder, and individuals with this condition vary considerably in terms of 
symptom presentation. This heterogeneity contributes to the difficulty faced by researchers 
and clinicians in trying to determine the precise underlying mechanisms and treatment for 
this condition. Furthermore, it remains unknown whether the variations in symptom 
manifestation are attributed to differences in underlying etiologies of the disorder or other 
factors as yet to be identified.  
Currently, it is believed that ASD is likely due to the interaction between different 
genetic and environmental factors. The maternal immune system is one example of where 
the environment may act upon genetic predispositions and lead to altered fetal brain 
development. Considering the importance of the immune environment during fetal 
development, maternal antibodies (Abs) directed against fetal proteins have been 
considered as potentially playing a critical function in the pathology of ASD.  
This thesis examines the literature focused on the role of maternal Abs in fetal 
development and their impact on the neuropathology of ASD. Studies have collected 
samples from mothers of children diagnosed with ASD and examined the reactivity 
patterns of the maternal Abs against fetal proteins. Through review and inspection of 
  vi
methodologies and results, this thesis highlights the important insights obtained as well as 
proposes possible reasons for the disparity in findings. Lastly, this thesis proposes future 
directions and therapeutic implications of identifying the maternal Abs that could be 
involved in at least a subset of ASD cases.  
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INTRODUCTION 
 
Given the high prevalence of autism spectrum disorder (ASD), which currently 
affects one in every 68 children, it is imperative to continue research efforts in this field 
(CDC, 2014). Furthermore, ASD is an extremely heterogeneous disorder as patients with 
ASD vary considerably in symptom presentation. As there are currently no diagnostic tools 
to determine the underlying biological basis of ASD, it remains unknown whether these 
variations in symptom manifestation are attributed to differences in underlying etiologies 
of the disorder or actually have similar underlying causes (Braunschweig & Van de Water, 
2012).  
Many boys with Fragile X Syndrome (FXS) exhibit autistic behaviors, and around 
25 percent of males with FXS could also be diagnosed as having autistic disorder using the 
Diagnostic and Statistical Manual of Mental Disorders (DSM), Fourth Edition (DSM-IV) 
(Bailey et al., 1998). Furthermore, genetically modified mice with the fragile x mental 
retardation 1 (Fmr1) gene knocked out display autistic-like behaviors, such as deficits in 
social cognition and interactions (McNaughton et al., 2008; Verkerk et al., 1991). A 
number of other genes have also been suggested as risk factors for autism, including the 
methyl-CpG-binding protein 2 (MeCp2) gene, typically associated with Rett syndrome, 
which falls under the category of ASD (Gadad, Hewitson, Young, & German, 2013). 
Another gene implicated in ASD is the tuberous sclerosis complex (TSC) gene, and mice 
with mutations in the TSC 1 (TSC1) gene demonstrate autistic-like behavioral activity 
(Tsai et al., 2012). The Reelin gene is additionally tied to autism (Serajee, Zhong, & 
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Mahbubul Huq, 2006). While numerous genetic mutations have been connected to ASD, 
these ASD-associated genetic mutations only account for a minor subset of patients with 
autism (Persico & Napolioni, 2013). Thus, ASD is likely due to the interaction between 
various genetic and environmental components (Figure 1).  
 
 
Figure 1. Interplay of genetics and the environment in the etiology of autism. Instead 
of being solely attributed to a single gene, autism is thought to be the result of the 
convergence of both genetic and environmental factors.  
 
 The immune system is an example of how the environment acts upon genetic 
predispositions and leads to altered brain development (Figure 2). Animal models have 
shown that pharmacological treatment with compounds, such as thalidomide, leads to 
dysfunction in immunological processes (Schneider et al., 2008). Thalidomide is an agent 
that has been used to treat various diseases, including cancer and other inflammatory 
conditions (Franks, Macpherson, & Figg, 2004). Exposure to viruses additionally leads to 
increased production of cytokines, which can alter neurotransmitter release (Libbey, 
 3 
Sweeten, McMahon, & Fujinami, 2005). Chemokines and cytokines are signaling proteins 
that are involved in the immune response (Borish & Steinke, 2003). Maternal immune 
activation leads to increased expression of chemokines and cytokines in ASD offspring, 
and elevated plasma levels of these immune factors are linked to greater impairments in 
communication (Borish & Steinke, 2003; Patterson, 2011). 
 
Figure 2. Contribution of genetics and the environment on immune system function 
and neurodevelopment. Various environmental and genetic factors act on the immune 
system, which consequently alters neurodevelopment, contributing to ASD risk. Taken 
from (Gadad et al., 2013).  
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Immunological disruption in particular has been implicated in ASD. Early studies 
noted an impact of dysfunction in T cell function (Stubbs & Crawford, 1977), infections 
from cytomegalovirus (Stubbs, 1978), as well as a decreased amount of antibodies (Abs) 
directed against Herpes simplex virus in ASD (Jorgensen & Menne, 1982).  
The fetal environment is known to be important for brain development. Abs are 
known to be transferred to the fetus at higher concentrations during the middle of the 
gestation period and ultimately increase to levels greater than those in the mother due to 
contribution of the FC receptors (Covington et al., 2009; Garty, Ludomirsky, Danon, Peter, 
& Douglas, 1994). FC receptors bind to a specific region on Abs and mediate active 
transport of these maternal Abs from the placenta (Covington et al., 2009; Garty et al., 
1994; Roopenian & Akilesh, 2007).  
Maternal Abs may serve a protective role during pregnancy by providing the baby 
with a way to respond to exposures in the environment until the child can develop his own 
adaptive immune defense system. In some situations, however, Abs can inflict harm to the 
developing fetus (Braunschweig & Van de Water, 2012). During instances of maternal 
autoimmunity, Abs capable of targeting proteins inherently produced by the mother herself 
may cross the placenta to the fetus, ultimately resulting in the fetus developing an 
autoimmune condition, possibly the one the mother may have, for example, myasthenia 
gravis (O'Carroll, Bertorini, Jacob, Mitchell, & Graff, 2009). Yet, manifestation of this sort 
of disease is relatively rare, as the baby’s circulation can remove these aberrant maternal 
Abs after birth during the first half year of life. However, if there is a disruption in the 
function of Abs during processes in which they are especially important, as is the case with 
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development, the effects can be nonreversible (Braunschweig & Van de Water, 2012). It 
has been reported that in neonatal systemic lupus erythematosus (SLE), transfer of maternal 
Abs against a form of a RNA-containing ribonucleoprotein can prevent the heart from 
developing normally, and the infant will ultimately need to undergo restorative surgery 
(Perez et al., 2011). Children of mothers with SLE have been found to have a higher risk 
of having ASD compared to children in the general population, lending further support for 
the possible role of autoimmune dysfunction in the development of ASD in a subset of 
individuals (Vinet et al., 2015).  
Additional evidence for disruption of the immune system in autism includes the 
associations found between autoimmune conditions, such as rheumatoid arthritis in 
parents, and autism diagnosis in the offspring (Comi, Zimmerman, Frye, Law, & Peeden, 
1999). In particular, autoimmune conditions in mothers, including psoriasis, have been 
linked to ASD in children (Croen, Grether, Yoshida, Odouli, & Van de Water, 2005). These 
data highlight the susceptible period of pregnancy and its effects on potential autism 
manifestation in the offspring. 
Imbalance in the mother’s immune system in pregnancy elevates the risk of autism 
in the children, and a number of factors have been implicated in an immune system 
becoming dysregulated (Meltzer & Van de Water, 2017). For example, maternal exposure 
to certain infections may alter the immune system by increasing the number of circulating 
cytokines, which can negatively impact the developing fetus (Figure 3).  
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Figure 3. Factors and effects of maternal immune dysregulation. Figure taken from 
(Meltzer & Van de Water, 2017).  
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Thus, considering the importance of the immune environment in fetal development, 
maternal Abs directed against fetal proteins may play a part in the etiology of at least a 
portion of ASD cases. 
Abs are transported from the mother’s blood through the placenta to the developing 
fetus and cross the fetal blood-brain barrier, which selectively allows for the passage of 
only certain cells and molecules from the circulation to enter the central nervous system. 
The adult blood-brain barrier typically prevents the entry of inflammatory factors, 
including Abs (Braunschweig & Van de Water, 2012; Liebner, Czupalla, & Wolburg, 
2011). The developing central nervous system of a fetus may not have a fully functioning 
blood-brain barrier due to signaling molecules that are still helping shape the blood-brain 
barrier’s exclusionary characteristics. Thus, the developing blood brain barrier may allow 
maternal Abs to enter the fetal brain. Variations in genes encoding for such signaling 
molecules could be involved in the role maternal Abs play in the development of ASD 
(Braunschweig & Van de Water, 2012).  
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Specific Aims 
Given the strong evidence for the maternal transfer of Abs to the fetus during 
development, this literature review seeks to examine what research has been conducted 
thus far and the direction in which the field is heading. The specific aims of this thesis are 
to:  
1.) Review studies pertaining to the role of maternal Abs in ASD.  
2.) Examine the methods used in these studies and suggest potential reasoning for 
differences in findings to date.  
3.) Discuss future directions and therapeutic implications.  
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PUBLISHED STUDIES 
 
 There has been growing interest in the study of maternal Abs in ASD, with most of 
the research in this field having been conducted within the past decade (Figure 4). 
However, the research examining the role of the mother’s Abs in ASD began with the 
hallmark study conducted by Warren and colleagues in 1990 (Warren et al., 1990). 
 
Figure 4. Studies on maternal Abs in ASD. Despite a 13-year gap during the years 
between 1991 and 2002, there has been increasing interest in studying the involvement of 
maternal Abs in ASD. To date, 26 studies have been carried out in this area.  
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Anti-fetal lymphocytes 
 
Warren and colleagues (1990) found that serum samples from more than half of 
mothers (6 out of 11) with at least one child with infantile autism displayed Ab reactivity 
against their children’s monocyte cells. The researchers also discovered a link between the 
mother’s Ab reactivity and any pregnancy complications, including miscarriage and 
bleeding of the uterus, shedding light on the importance of the prenatal gestational period 
(Warren et al., 1990).  
Twenty-two years later, Bressler and colleagues (2012) used flow cytometry to 
assess mothers’ Ab reactivity to her children’s peripheral monocyte cells (Bressler et al., 
2012). This study compared Ab reactivity of mothers who gave birth to both children later 
diagnosed with autism and children without autism or any other neurodevelopmental 
disorder. The researchers found that the reactivity of Abs from the mothers to their autistic 
children’s monocytes did not vary from that seen when the maternal Abs reacted with the 
non-autistic children’s monocyte cells. The difference in findings from Warren and 
colleagues (1990) and Bressler and colleagues (2012) could be attributed to Warren and 
colleagues (1990) including a more homogenous group of autism samples as well as 
differences in the methodology used (Bressler et al., 2012; Warren et al., 1990).  
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Transfer of maternal Abs into animal models 
Mouse models  
 
A number of studies have examined the role of the mother’s Abs in the development 
of ASD through the use of animal models. Dalton and colleagues (2003) administered 
serum collected from mothers of at least one child with ASD into pregnant mice and 
discovered that the pups displayed behavioral and motor impairments compared to controls 
(Dalton et al., 2003). Similarly, Singer and colleagues (2009) injected pregnant mice on 
days 13-18 of gestation with Abs from mothers of children diagnosed with or without 
autistic disorder. The offspring of the pregnant mice injected with Abs from mothers of 
children diagnosed with autistic disorder were found to have deficits in social behaviors, a 
heightened acoustic startle response, increased activity, and behaviors related to anxiety 
compared to control mice (Singer et al., 2009). Furthermore, Kadam and colleagues (2013) 
uncovered greater cellular proliferation in the sub-ventricular zone and sub-granular zone 
but decreased cellular density in frontal and parietal cortical areas compared to the control 
group in the postnatal brains of mice that were prenatally administered Abs collected from 
mothers of autistic children (Kadam et al., 2013).  
In a study conducted by Camacho and colleagues (2014), following intraventricular 
administration of Abs specific for 37 and 73 kdA proteins in the fetal brain (obtained from 
samples from mothers of children diagnosed with autistic disorder), mice displayed more 
grooming behaviors after being put in a novel area and buried a greater number of marbles, 
suggesting autistic-like stereotypical and repetitive behaviors, respectively, compared to 
mice injected with Abs that came from mothers of children without autistic disorder 
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(Camacho et al., 2014). However, this study did not discover any significant impairments 
in social interactions for the mice that were administered Abs from mothers of autistic 
children compared to mice given Abs from mothers of children without ASD. In addition, 
there were no differences in locomotor activity between the two groups of mice, lending 
support to the fact that these findings were not attributed simply to hyperactivity (Camacho 
et al., 2014). 
 
Non-Human Primate (NHP) models 
 While mouse models are important for neurobiological research, studies conducted 
in NHPs also provide extremely valuable information as they more closely resemble 
humans. In particular, because ASD is a condition associated with deficits in social 
interaction and NHPs display social behaviors such as facial expressions and gestural use 
as ways to communicate, NHP models are an ideal animal model for studying this disorder 
(Watson & Platt, 2012). Furthermore, given that NHP brains are more developed than 
rodents, brain regions implicated in ASD are better able to be studied using NHP models 
(Bauman et al., 2013).  
 As such, Martin and colleagues (2008) examined the impact of exposing pregnant 
NHPs during the gestational phase to Abs obtained from human mothers of children with 
ASD (Martin et al., 2008). Pregnant NHPs were injected with Abs that came from mothers 
of ASD children, and these Abs recognized brain proteins important in fetal development. 
The control groups were NHPs administered Abs from mothers of children who did not 
have ASD as well as NHPs that were not administered any Abs. The Abs were 
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intravenously administered three times over the course of gestation. These researchers 
found that offspring from NHPs exposed to Abs from the mothers of ASD children showed 
little differences in social interactions but had greater activity and stereotypical behaviors 
than the control NHP groups in this study (Martin et al., 2008).  
 In a similar study, Bauman and colleagues (2013) investigated the effects of 
transferring Abs from mothers of ASD children or mothers of typically developing children 
during the first and second trimesters (six injections were made during early and middle 
gestation), and behavioral changes in the NHP offspring was examined over the subsequent 
two years. This study did not find any differences in repetitive behaviors but found that 
offspring of NHPs administered anti-fetal brain Abs from mothers of autistic children had 
more abnormalities in social interactions (Bauman et al., 2013).  
 
Anti-thyroid peroxidase 
Thyroid peroxidase is a type of glycoprotein found in the apical membrane of 
thyroid epithelial cells. In some individuals, presence of this protein can induce production 
of thyroid peroxidase Abs, which have been implicated in autoimmune disorders, such as 
Hashimoto’s thyroiditis (Hadj-Kacem et al., 2009; Ruf & Carayon, 2006). Children of 
mothers with the presence of thyroid peroxidase Abs during pregnancy have been shown 
to exhibit impaired verbal and cognitive ability (Pop et al., 1995). Thus, Brown and 
colleagues (2015) measured the levels of thyroid peroxidase Abs in serum samples 
collected from pregnant mothers who were in the first and second trimesters. This study 
found that there was an increased chance of developing autism in children from mothers 
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who had shown expression of thyroid peroxidase Abs during the first and second trimesters 
of pregnancy compared to mothers who did not have levels of these Abs during that 
developmental period. In addition, there was no significant relationship between thyroid 
peroxidase Abs in mothers and preterm deliveries, lower birthweights, and the mother’s 
weight during gestation. This further implicates the critical time of the prenatal compared 
to the perinatal and postnatal periods for fetal development and potential susceptibility for 
increased autism risk. Furthermore, there was no relationship between autism and maternal 
hypothyroidism, hyperthyroidism, thyroid stimulating hormone, or free thyroxine, thus the 
association between the mother’s thyroid peroxidase Abs levels and autism was not 
explained by the mother’s thyroid hormone levels (Brown et al., 2015). However, this is in 
contrast to findings from a study led by Román and colleagues (2013) who found that 
severe hypothyroxinemia in mothers was linked to autistic symptoms in children, as 
reported by the parents, but that the presence of thyroid peroxidase Abs were not shown to 
be associated with autistic symptoms (Román et al., 2013). Yet, the discrepancy in findings 
between these two studies could be attributed to the difference in sizes of samples used as 
well as the diagnostic standards set for defining autism (Brown et al., 2015).  
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Implications of genetics for the mother’s Abs 
It is believed that ASD pathology may have an underlying genetic component, 
potentially in the form of polymorphisms in genes pertaining to immunological 
responsivity (Goines & Van de Water, 2010). In particular, impairments in immune 
tolerance occurs when the immune system is unable to prevent assembly of self-directed 
Abs, which could be the reason for cases in which self-reactive Abs are able to be produced 
and exert detrimental effects. Heuer and colleagues (2011) found that polymorphisms in 
the MET gene, a factor typically important in regulating immune tolerance by reducing 
expression of MET protein, were highly associated with the maternal Abs directed against 
the fetal brain proteins at 37 and 73 kDa present in the mothers of children with ASD 
diagnoses (Heuer, Braunschweig, Ashwood, Van de Water, & Campbell, 2011). 
Braunschweig and colleagues (2012) additionally revealed that Abs that came from 
mothers of ASD children and that were reactive at the 37 and 73 kDa protein bands were 
linked to children displaying more deficits in expressive language (Braunschweig, 
Duncanson, et al., 2012). 
 
Anti-folate receptors 
Folate receptors, which are seen extensively in the placenta and brain, are important 
for brain and overall fetal development (V. Ramaekers, Sequeira, & Quadros, 2013). When 
these receptors are blocked by folate receptor alpha Abs, as is evident in children with 
cerebral folate deficiency, there are decreased concentrations of folate in the cerebrospinal 
fluid because folate cannot be transferred across the choroid plexus (V. T. Ramaekers et 
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al., 2005). In addition, previous research has revealed that administering folate receptor 
alpha Abs to rats during the gestational period and early developmental period, before the 
animals are weaned, leads to behavioral deficits that have been tied to ASD (Desai, 
Sequeira, & Quadros, 2017; Sequeira et al., 2016). Furthermore, a link has been found 
between these Abs and both children diagnosed with ASD and their parents (Frye, 
Sequeira, Quadros, James, & Rossignol, 2013; Frye et al., 2018; V. T. Ramaekers, 
Quadros, & Sequeira, 2013). Given these findings, Quadros and colleagues (2018) recently 
extended these findings to families that include a child diagnosed with having ASD 
(Quadros et al., 2018). This study revealed a high percentage of Ab levels across families 
of children with ASD diagnoses, not just in the affected children and the mothers (Quadros 
et al., 2018).  
 
Anti-contactin-associated protein-like 2 (CASPR) 
CASPR2 is an essential protein for brain development, particularly for appropriate 
neuronal circuitry by regulation of dendritic processes (Anderson et al., 2012). Variations 
in the gene coding for CASPR2 have been shown to be expressed in individuals with ASD 
and other neurodevelopmental disorders (Rodenas-Cuadrado, Ho, & Vernes, 2014). A 
study by Brimberg and colleagues (2016) revealed that CASPR2 Abs were present in 37 
percent of serum samples obtained from mothers of children diagnosed with ASD, whereas 
the control group of mothers only showed an 8-12 percent expression of these Abs. 
Administering a clonal version of the maternal CASPR2 Ab in mice during gestation 
revealed patterns of autistic-like behaviors in the male offspring of these mice (Brimberg 
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et al., 2016). However, a recent study conducted by Coutinho and colleagues (2017) did 
not find an elevation of CASPR2 Abs in mothers of children diagnosed with ASD, as only 
one of the 95 samples of mothers of children diagnosed with ASD showed expression of 
these Abs (Coutinho et al., 2017). This study did, however, find maternal CASPR2 Abs to 
be linked to children with intellectual disability or other disorders of psychological 
development (Coutinho et al., 2017). Thus, all together these studies do provide support 
for the potential role of CASPR2 in neurodevelopment disorders.  
 
Anti-cerebellum 
A study conducted by Goines and colleagues (2011) used a large cohort of children 
who were put into three categories: autistic disorder, the broader diagnosis of ASD, or 
confirmed as being typically developing children (Goines et al., 2011). This study revealed 
an association between presence of anti-cerebellar Abs targeting a 45 kDa protein and the 
diagnosis of autistic disorder, whereas expression of an Ab specific for a 62 kDa protein in 
the cerebellum was linked to the broader diagnosis of ASD. Furthermore, the children who 
expressed these kinds of Abs, regardless of the diagnosis they were given (autistic disorder 
or ASD), exhibited impairments in adaptive and cognitive functioning and greater aberrant 
behaviors than children who did not express these Abs. In particular, children with Abs 
targeting the 45 kDa expressed more stereotypical behaviors and lethargy compared to 
children lacking this sort of Ab reactivity. Additionally, children with Ab reactivity 
directed against the 62 kDa protein, irrespective of diagnosis status, demonstrated more 
problems of abnormal speech compared to children who lacked this Ab reactivity. 
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Moreover, children diagnosed with ASD who had Abs reactive for the 62 kDa cerebellar 
proteins had more aberrant behaviors overall as well as greater lethargy and stereotypical 
behaviors. Lastly, typically developing children who possessed reactivity against the 62 
kDa protein had more impaired adaptive functioning than children without Ab reactivity. 
This difference may be the result of these proteins playing distinctive roles in different 
pathways leading to the manifestation of particular behaviors, i.e. if the 62 or 45 kDa 
protein is affected, this may lead to a behavioral profile more consistent with autistic 
disorder, which is associated with having more severe symptoms, or the broader diagnosis 
of ASD, which is held to be less severe. This study added additional support to the 
hypothesis that maternal Abs may target specific fetal brain proteins, resulting in autism-
like conditions in their children. In particular, 10.8 percent of mothers of children who were 
diagnosed with having autistic disorder, 4.6 percent of mothers of children diagnosed with 
ASD, and zero percent of mothers of non-autistic children showed Ab reactivity patterns 
directed against both of these fetal proteins. In addition, this study found that having both 
Abs specific for the 39 kDa as well as the 73 kDa proteins in the fetal brain was associated 
with the child having the diagnosis of autistic disorder or ASD (7.7 percent of mothers of 
children with autistic disorder, 12.3 percent of mothers of ASD children, and 1.7 percent 
of mothers of typically developing children revealed Ab reactivity against both of these 
types of fetal brain proteins). Furthermore, mothers of children diagnosed with autistic 
disorder or ASD possessed Abs targeting significantly more proteins in the fetal brain when 
compared to mothers of typically developing children. However, this study did not find 
any definite association between mothers having Ab reactivity towards the 39 and 73 kDa 
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or 37 and 73 kDa proteins in the fetal brain with children who have Ab reactivity towards 
the 45 or 62 kDa cerebellar proteins, suggesting these immune processes may be due to 
different processes (Goines et al., 2011).  
 
Anti-brain 
Studies have also looked at the impact of maternal Abs directed against overall fetal 
brain proteins in ASD. A study conducted by Zimmerman and colleagues (2007) revealed 
that mothers of children with ASD diagnoses exhibited Ab reactivity that persisted up to 
18 years after giving birth (Zimmerman et al., 2007). Abs targeted against the 37 and 73 
kDa brain proteins as the fetus develops have been found to be expressed in some mothers 
of children diagnosed with autism (Braunschweig et al., 2008). This finding of maternal 
Ab reactivity for the 37 and 73 kDa proteins has also been shown when analyzing a greater 
number of samples (Braunschweig, Duncanson, et al., 2012). The pattern of maternal Ab 
reactivity at 39 and 73 kDa in the fetal brain is also uniquely found from samples of mothers 
of autistic children and not from mothers of typically developing children (Braunschweig, 
Duncanson, et al., 2012; Croen et al., 2008).  
Extending this research, Rossi and colleagues (2013) found that plasma obtained 
from mothers of Spanish children with ASD diagnoses uniquely expressed reactivity 
patterns for the 37 and 73 kDa proteins as well as the 39 and 73 kDa proteins, which 
mothers of typically developing children did not (Rossi, Fuentes, Van de Water, & Amaral, 
2013). Similarly, Piras and colleagues (2014) found that the presence of Abs reactive for 
the 37, 39, and 73 kDa proteins in the fetal brain were linked to language impairments in 
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Italian children with ASD diagnoses (Piras et al., 2014). Thus, these findings seem to be 
found in different countries, despite different cultures and genetic makeup (Rossi et al., 
2013).  
In addition, Croen and colleagues (2008) looked at blood samples from pregnant 
women during the middle of gestation and examined the Abs present in the samples of 
those mothers who afterwards delivered birth to children diagnosed with ASD (Croen et 
al., 2008). These maternal Abs have been shown to impact fetal brain development 
(Braunschweig et al., 2013). Taking this one step further with evidence that mothers with 
autoimmune conditions have been found to be more likely to have children with ASD, 
Brimberg and colleagues (2013) investigated whether mothers of children with ASD 
diagnoses would have increased expression of anti-brain Abs as well as if this Ab reactivity 
would be associated with the mother’s history of autoimmune conditions (Brimberg, Sadiq, 
Gregersen, & Diamond, 2013). This study used a large cohort of maternal samples and 
discovered an association between anti-brain Ab reactivity and autoimmune disorders as 
well as increased levels of these Abs in mothers of children who have ASD diagnoses 
(Brimberg et al., 2013).  
 Singer and colleagues (2008) discovered that mothers of children diagnosed with 
autism had greater Abs reactive at the 36 kDa protein in in the fetal brain (both human and 
rodent). Furthermore, there was more reactivity seen against 36 and 39 kDa proteins in the 
human fetal brain in mothers of children diagnosed with autism and regression (Singer et 
al., 2008). This begs the question of whether autism and regression diagnoses in children 
are linked to a pattern of maternal Ab reactivity that is different from that associated with 
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children with autism but without regression. 
 
Abs against specific brain proteins  
A study conducted by Ali and colleagues (2016) showed a significant association 
between maternal Abs for cerebellar (Yo) and neuronal (amphiphysin) proteins and 
children diagnosed with ASD, and that levels of these Abs were much greater in mothers 
of children who had ASD diagnoses compared to mothers of typically developing children 
(Ali, Khalaf, Al-Asadi, & Abed, 2016). While Brimberg and colleagues (2013) found an 
association between maternal autoimmune disorder history and maternal anti-brain Ab 
reactivity in mothers of children who had ASD diagnoses, other work has not found such 
a relationship (Ali et al., 2016; Croen et al., 2008). Additional studies will need to be 
conducted to elucidate the role of both the mother’s autoimmune history and presence of 
maternal Abs in ASD risk.  
Lactate dehydrogenase A and B (LDH), stress-induced phosphoprotein 1 (STIP1), 
cypin, as well as collapsin response mediator proteins 1 and 2 (CRMP1 and CRMP2, 
respectively) are proteins that are present during brain development at high concentrations 
(Figure 5). Cypin affects dendritic branching, and thus Abs for cypin would disrupt the 
formation of dendritic spines during development (Braunschweig et al., 2013). In fact, 
post-mortem findings have revealed increased spine density in pyramidal cells in some 
individuals with ASD (Hutsler & Zhang, 2010). STIP1 is involved in neurogenesis, while 
CRMP1 and CRMP2 are implicated in processes such as cell migration and growth cone 
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migration (Charrier et al., 2003; Lopes et al., 2005; Quach et al., 2004). LDH plays a part 
in inflammatory processes (Shin et al., 2010; Silva et al., 2006)  
 Braunschweig and colleagues (2013) have attempted to determine the identity of 
antigen proteins that are targeted by Abs in mothers who express Ab reactivity against fetal 
NHP brain at day 153 of gestation. Using Western Blot analysis, the researchers determined 
that mothers of ASD children had significantly more instances of reactivity against LDH 
(corresponding to the 37 kDa band pattern) compared to mothers of typically developing 
children. Close to 23 percent of mothers of children diagnosed with ASD expressed a 
combination of three or more antigen-specific Ab patterns compared to mothers of 
typically developing children who, for the most part, did not (only two mothers of the 149 
showed this reactivity pattern). In particular, a significant relationship was found between 
expression of Abs for CRMP1, CRMP2, STP1 and children having an ASD diagnosis. 
Additionally, there were particular patterns of Ab reactivity that were unique to the mothers 
of children with ASD compared to controls. For example, Ab reactivity against the 
combination of LDH, STIP1, and CRMP2 (corresponding to the 37 and 73 kDa band 
pattern) was found in 5 percent of mothers of children diagnosed with ASD compared to 
zero percent expression in mothers of typically developing children. Additionally, the 
combination of reactivity against LDH, STIP1, CRMP1, and cypin was found in 2 percent 
mothers of ASD children and zero percent of mothers of typically developing children. 
Furthermore, there were more stereotypical behaviors in children whose mothers had Ab 
reactivity against LDH, CRMP1, or to the combination of LDH, STIP1, and CRMP1 
compared to children whose mothers did not possess Abs targeting these fetal brain 
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proteins. Thus, these findings lend further support for the role of these proteins in the 
behavioral impairments associated with ASD. This study differs from most other studies 
reviewed here in that it illustrates the increased sensitivity for identifying Abs afforded by 
use of pure antigens as the targets compared to when crude proteins from fetal samples are 
used.  
 
 
Figure 5. Functions of neurodevelopmental proteins targeted by maternal Abs. By 
reacting with their specific protein targets, Abs may interrupt such critical processes that 
occur during development and possibly contribute to manifestation of symptoms linked to 
ASD. Taken from (Braunschweig et al., 2013) 
  
 24 
DISCUSSION 
 
Differences in techniques  
The studies reviewed here have examined maternal Abs implicated in fetal 
development and their potential role in the etiology of autism. However, there are many 
different techniques used in these studies (Figure 6). The majority (58 percent) of studies 
have employed immunoblotting, also known as the Western Blot. Two studies (8 percent) 
have used flow cytometry, while the other 19 percent have utilized other techniques, such 
as enzyme-linked immunosorbent assay (ELISA), chemiluminescent micro-particle 
immunoassays, immunofluorescence, and complement-dependent assays. Other studies 
(15 percent) have used Ab reactivity from previous studies instead of running assays again. 
As there are a limited number of studies in this relatively new area of research, it is 
imperative to replicate techniques to determine which findings and techniques seem to be 
most reliable.  
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Figure 6. Techniques used in studies investigating the implication of maternal Abs in 
fetal development and the etiology of ASD. Percentages were calculated based on the 
number of studies using particular methods out of the 26 studies looking at the role of 
maternal Abs in the etiology of ASD. Other techniques refer to: immunofluorescence, 
chemiluminescent micro-particle immunoassays, enzyme-linked immunosorbent assay 
(ELISA), and complement-dependent cytotoxic assays.  
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In addition to the variation in techniques utilized, studies have been split on whether 
maternal plasma or serum samples were collected (Table 1, in Appendix I). Again, since 
there are only a limited number of studies published in this area, consistency in method is 
important in drawing conclusions. The temperature and length of time for which samples 
are stored is an important factor to consider. For example, Brown and colleagues (2015) 
mentioned that storing samples for a longer period of time may lead to decreased Ab 
reactivity (Brown et al., 2015).  
Depending on the methodologies used in studies, the results obtained can differ. 
For example, Wills and colleagues (2009) found Abs specific for a cerebellar protein at 52 
kDa in ASD children, yet in a follow-up study, Goines and colleagues (2011) found that 
Abs were specific for a cerebellar protein at 45 kDa (Goines et al., 2011; Wills et al., 2009). 
Goines and colleagues repeated some of the plasma samples used in the 2009 study 
conducted by Wills and colleagues with a newer, updated western blotting tool as well as 
another type of molecular weight maker method utilized in their 2011 study. The pattern 
obtained with the newer method yielded the cerebellar protein band at 45 kDa as found in 
the newer study. Thus, as newer technologies and platforms are being developed, these 
should be evaluated against older methods to determine which tools and techniques capture 
data most accurately.  
 
Creating a more encompassing picture of ASD risks 
Since the risks of developing autism continue to be investigated, it is important to 
collect additional information that may pertain to autism risk. For example, in addition to 
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gathering information on maternal age, some studies have also collected information 
pertaining to socioeconomic status, birthweight, whether birth was preterm, gestational 
weight, family history of psychiatric disorders, maternal smoking history, and maternal 
education level (Brown et al., 2015; Román et al., 2013). Other studies have included 
information on maternal medication history, especially any medications known to affect 
the immune system, and whether these types of drugs were taken during pregnancy. 
Obtaining any history of maternal or familial immune disorders is also important (Ali et 
al., 2016; Braunschweig, Duncanson, et al., 2012; Singer et al., 2008; Zimmerman et al., 
2007). In a study conducted by Zimmerman and colleagues (2007), some mothers of ASD 
children were also diagnosed with autoimmune conditions, including SLE and rheumatoid 
arthritis (Zimmerman et al., 2007). Including these additional groups of mothers with such 
autoimmune conditions allows for further investigation of the maternal immune component 
in ASD to help create a better picture of the risks and etiology of this disorder.  
 
ASD Classification  
Another factor that could influence the findings obtained in these studies is how 
ASD is defined and the diagnostic tools used for classification. The diagnostic approaches 
for the studies reviewed in this thesis are summarized in Table 1 (Appendix I). The earliest 
study reviewed here examined mothers of children diagnosed with infantile autism, based 
on the definition in the DSM, Third Edition (DSM-III) and used the Autism Behavior 
Checklist and the Differential Abilities Test to determine intelligence quotient (IQ) 
(Warren et al., 1990). Other studies have also included mothers of children diagnosed with 
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autism or autistic disorder using the criteria defined in the DSM-IV, DSM-IV, Text Revised 
(DSM-IV-TR), or the International Classification of Diseases, Tenth Edition (ICD-10) 
criteria (Ali et al., 2016; Braunschweig et al., 2008; Braunschweig, Duncanson, et al., 2012; 
Braunschweig, Golub, et al., 2012; Bressler et al., 2012; Brown et al., 2015; Goines et al., 
2011; Kadam et al., 2013; Singer et al., 2009; Singer et al., 2008). Of those studies, some 
have indicated whether they specifically excluded conditions such as Asperger’s Disorder, 
autism cases with known metabolic or genetic etiologies, and Pervasive Developmental 
Disorder, Not Otherwise Specified (PDD-NOS) (Bressler et al., 2012; Brown et al., 2015; 
Kadam et al., 2013; Singer et al., 2009; Singer et al., 2008). Other studies have included 
mothers of children diagnosed with ASD also using the DSM-IV, DSM-IV-TR, or the ICD-
10 for making diagnoses (Braunschweig, Duncanson, et al., 2012; Braunschweig et al., 
2013; Coutinho et al., 2017; Croen et al., 2008; Goines et al., 2011; Heuer et al., 2011; 
Piras et al., 2014; Quadros et al., 2018; Rossi et al., 2013; Zimmerman et al., 2007). 
Additionally, studies have further specified if ASD children were diagnosed with high-
functioning autism (HFA) or low-functioning autism (LFA) as well as if they had 
regression or epilepsy (Dalton et al., 2003; Zimmerman et al., 2007). Quadros and 
colleagues (2018) noted that ASD cases included Asperger’s Disorder and PDD-NOS 
(Quadros et al., 2018). This is consistent with the current definition of ASD as defined by 
the most recent version of the DSM (DSM Fifth Edition, DSM-5), which allows for the 
diagnoses of PDD-NOS and Asperger’s Disorder (APA, 2013).  
Diagnoses have been made using a variety of diagnostic tools, including: the 
Autism Diagnostic Interview (ADI) and ADI-Revised (ADI-R), the Autism Diagnostic 
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Observation Schedule (ADOS) and ADOS-Generic (ADOS-G), the Social Communication 
Questionnaire (SCQ), the Aberrant Behavior Checklist (ABC), the Childhood Autism 
Rating Scale (CARS), the Vineland Adaptive Behavior Scale (VABS), the Pervasive 
Developmental Problems (PDP) domain of the Child Behavior Checklist (CBCL), the 
Social Responsiveness Scale (SRS), and the Autism Behavior Checklist. 
ASD is an extremely heterogeneous disorder, and efforts should be made to 
continue trying to stratify these groups into subtypes. Since many studies have either 
selected to use either ASD or autistic disorder definitions for inclusion criteria, it will be 
very helpful to have studies that include both of these groups. Some studies have already 
done this (Braunschweig, Duncanson, et al., 2012; Goines et al., 2011; Martin et al., 2008). 
Such studies and additional examination of data following group stratification will help to 
move the identification of meaningful subtypes of ASD forward.  
 
Control group classification 
Not all studies that looked at maternal Abs in ASD have included mothers of control 
children (Bressler et al., 2012; Piras et al., 2014; Quadros et al., 2018; Warren et al., 1990), 
and some have included women of childbearing age who have not yet had any children 
(Brimberg et al., 2016; Brimberg et al., 2013). Most studies have included mothers of 
typically developing children, but it is not always specified how typically developing is 
defined. A few studies have gathered familial history and medication use from control 
mothers (Singer et al., 2008; Zimmerman et al., 2007).  
 30 
There have also been studies that used diagnostic tools to define the control group, 
such as the SCQ (Braunschweig et al., 2008; Braunschweig, Duncanson, et al., 2012; 
Braunschweig et al., 2013; Braunschweig & Van de Water, 2012; Goines et al., 2011; 
Heuer et al., 2011; Rossi et al., 2013). In addition to the SCQ, studies have collected scores 
from the Mullen Scales of Early Learning (MSEL), VABS, and ABC for the typically 
developing children of control mothers (Braunschweig et al., 2008; Braunschweig, 
Duncanson, et al., 2012; Braunschweig et al., 2013; Braunschweig & Van de Water, 2012; 
Goines et al., 2011). Roman and colleagues (2013) gathered scores from children on the 
PDP domain of the CBCL and the SRS to differentiate between autistic and typically 
developing children (Román et al., 2013). The MSEL has also been used on both ASD 
children and typically developing children in some studies (Braunschweig et al., 2008; 
Braunschweig, Duncanson, et al., 2012; Braunschweig & Van de Water, 2012; Goines et 
al., 2011). Administering the same assessments to children who will be assigned into 
control and ASD groups is time consuming, but it allows for the comparison of scores on 
the same measures (i.e. to see any differences in severity) as well as further validate an 
ASD diagnosis (for ASD children) or negate such a diagnosis, as is desired for the control 
children. Having a well-defined control group for the mothers with typically developing 
children is important as this critically impacts any conclusions drawn about the mothers of 
ASD children group.  
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Determining the explanation for Ab reactivity in controls  
Future studies should further investigate why some control mothers express Ab 
reactivity patterns similar to those seen in mothers of ASD children even though control 
mothers did not deliver children with ASD, as meaningful information could be learned 
this way. For example, Goines and colleagues (2011) discovered that children who had 
Abs against cerebellar proteins showed greater deficits in cognitive, behavioral, and 
adaptive behaviors compared to children who did not have these Abs. This raises the 
possibility of the Abs being more involved in the behavioral patterns manifested in these 
children with these Abs rather than specifically linked to an autism diagnosis.  
In another study, approximately 89 percent of mothers of children diagnosed with 
ASD expressed Abs reactive to any of the antigen targets, whereas 70 percent of mothers 
of non-autistic children exhibited Ab reactivity patterns to any of the antigens 
(Braunschweig et al., 2013). Bressler and colleagues (2012) found that CASPR2 Abs were 
also seen in four control mothers, suggesting that other factors may need to be considered 
in determining whether Abs are pathological or not (Bressler et al., 2012). 
Despite the presence of Ab reactivity seen in mothers with non-autistic children, 
these control children were still classified as healthy. Perhaps behavioral impairments were 
evident in these children, or maybe in these cases there was a greater predisposition for 
these children to develop ASD. Yet, since this disorder is likely multifactorial, the 
contribution from the maternal Ab reactivity alone without any additional “hits” (e.g. 
genetic or environmental) probably is not enough to induce an ASD phenotype in the 
children.  
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Conclusions and future directions 
Finally, more studies should be conducted to investigate the precise clinical 
implications and underlying biological mechanisms of these Abs. The exact targets and the 
locations in which these targets are found should be investigated. For example, it would be 
important to establish whether the targets of these Abs are found throughout the brain or 
are restricted to specific brain areas. Future research should also explore if the Abs are 
linked to pathological processes by themselves or whether the presence of Abs is secondary 
to other underlying aberrant processes. If the Abs are in fact primarily pathogenic, they 
would need to cross the blood brain barrier to gain entry to the brain. Abs are large and do 
not typically enter the brain. Yet, under certain conditions, including infection and injury, 
the Abs may cross the blood brain barrier. Thus, if typically developing children also 
express Abs, it is possible that many factors may need to converge to result in the etiology 
of ASD. Typically developing children may not have experienced the additional insults 
needed to allow the passage of Abs into the brain that specifically act on the targets in the 
brain (Goines and colleagues 2011). If the Abs are secondary to some other pathology, the 
Abs could be used as a surrogate marker for autism in at least a small subset of individuals 
with ASD.  
Given the heterogeneity of ASD, it is imperative to continue stratifying patients 
into sub-groups for improved diagnosis and therapies. Perhaps, if the Abs are known, 
medical professionals could administer the protein that is being reduced (like reduced MET 
gene). For example, it has been shown that when children with cerebral folate deficiency, 
particularly those who have been diagnosed earlier as infants, are administered higher dose 
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of folinic acid, the treatment is more effective as the drug can displace the Abs blocking 
the receptors (V. Ramaekers et al., 2013). In addition, if it is known that parents are positive 
for particular Abs, then supplements could potentially be given prior to pregnancy and 
continual treatment could be given to mothers during the course of pregnancy to reduce the 
likelihood of the fetus developing conditions such as ASD (Quadros et al., 2018).  
 Since the study of maternal Abs in autism is still a relatively new area of research, 
more studies using consistent methods need to be conducted and carefully designed to 
include the diversity of ASD while also investigating the various subtypes that exist for 
this disorder. Identifying the targets of the maternal Abs along with using standardized 
diagnostic criteria for ASD and control subjects may allow for the development of prenatal 
screening and therapies for a subtype of ASD.  
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APPENDIX I 
 
Table 1. Aspects of studies looking at maternal Ab involvement in ASD. 
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APPENDIX I 
 
Table 1. Aspects of studies looking at maternal Ab involvement in ASD. 
Author Sample 
type  
Mothers of 
children w/ 
autism 
ASD 
diagnostic 
tools  
Maternal 
control/ 
comparison 
group 
Additional 
comments 
(Quadros et al., 
2018) 
Serum Mothers of ASD 
children 
(included autistic 
disorder, PDD-
NOS, childhood 
disintegrative 
disorder, and 
Asperger’s 
Disorder) 
DSM-IV/ 
DSM-IV-
TR, ADI-
R, ADOS-
G, VABS 
N/A Included 
mothers of 
boys and girls  
(Coutinho et al., 
2017) 
Serum Mothers of ASD 
children 
ICD-10: 
F84.0, 
F84.1, 
F84.5, 
F84.8, 
F84.9 
Mothers who 
delivered 
children w/out 
autism  
-Controls 
matched on 
maternal 
delivery age & 
gender of 
children 
-Samples from 
gestational 
weeks 14 & 18 
(Ali et al., 2016) Serum Mothers of 
children w/ 
autism 
ADOS,  
ADI-R, 
ICD-10/ 
DSM-IV 
Healthy 
mothers of 
typically 
developing 
children  
No 
medications 
reported at 
intake for all 
women 
(Brimberg et 
al., 2016) 
Plasma Mothers of ASD 
children 
Simons 
Simplex 
Complex  
Women of 
child-bearing 
age 
Age-matched 
control group 
mothers to 
mothers of 
autistic 
children 
(Brown et al., 
2015) 
Serum Mothers of 
children w/ 
childhood autism 
(excluded 
Asperger's 
ICD-10: 
F84.10, 
ADI-R, 
DSM-IV 
Mothers of 
children w/out 
ASD (no F84 
diagnosis) or 
severe IDD  
-Maternal 
samples from 
first & second 
trimesters. 
-Information 
collected on 
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Disorder and 
PDD-NOS) 
socioeconomic 
status, 
birthweight, if 
birth preterm, 
gestational 
weight, family 
history of 
psychiatric 
illness 
(Piras et al., 
2014) 
Plasma Mothers of 
children w/ ASD 
ADI-R, 
ADOS, 
VABS, 
IQ,  
ICD-10/ 
DSM-IV 
N/A - 
(Camacho et al., 
2014) 
Plasma Mothers of 
children w/ 
autistic disorder 
Not 
specified 
Mothers of 
typically 
developing 
children 
- 
(Rossi et al., 
2013) 
Plasma Mothers of 
children w/ ASD 
ADOS-G,  
ADI-R, 
ICD-10/ 
DSM-IV 
Mothers of 
children w/ 
scores < 18 on 
the SCQ 
-Subjects 
matched for 
age and 
gender.  
-All mothers 
screened for 
autistic 
characteristics 
using the 
autism 
quotient  
(Brimberg et 
al., 2013) 
Plasma Mothers of 
children w/ ASD 
Simons 
Simplex 
Complex 
Mothers of 
child-bearing 
age 
- 
(Bauman et al., 
2013) 
Serum Mothers of 
children w/ 
autism 
Not 
specified 
Mothers of 
typically 
developing 
children 
- 
(Braunschweig 
et al., 2013) 
Plasma Mothers of 
children w/ ASD 
ADOS, 
ADI-R, 
ABC, 
ICD-10/ 
DSM-IV 
Mothers of 
typically 
developing 
children 
(SCQ, MSEL, 
VABS, ABC) 
- 
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(Román et al., 
2013) 
Plasma Mothers with 
autistic children 
PDP 
domain 
of 
CBCL1½-
5, SRS 
Mothers of 
children not 
meeting the 
criteria of 
PDP domain 
of CBCL1½-
5, SRS 
-Samples 
collected 
during early, 
mid, and late 
pregnancy  
-Info collected 
on maternal 
education, 
birthweight, 
maternal 
smoking 
history, etc. 
(Kadam et al., 
2013) 
Serum Mothers of 
children w/ 
autistic disorder 
and moderately 
to severely 
impaired in 
cognitive or 
adaptive 
functioning 
(excluded PDD-
NOS and autism 
w/ known 
genetic/ 
metabolic 
etiologies) 
DSM-IV, 
ADOS-G, 
CARS, IQ 
Mothers of 
unaffected 
children 
- 
(Bressler et al., 
2012) 
Serum Mothers of 
children w/ 
nonverbal, 
moderate to 
severe autism 
(excluded autism 
w/ known 
genetic/ 
metabolic 
etiologies) 
ADOS, 
ADI-R, 
ICD-10/ 
DSM-IV 
N/A - 
(Braunschweig, 
Duncanson, et 
al., 2012) 
Plasma Mothers of 
children w/ 
autism or ASD 
 
Clinical 
diagnosis 
of autistic 
disorder, 
MSEL, 
VABS  
Mothers of 
typically 
developing 
children based 
on MSEL and 
VABS  
-Matched by 
maternal age, 
child sex and 
age 
-No noted 
immune 
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dysfunction 
history for all 
mothers 
(Braunschweig, 
Duncanson, et 
al., 2012; 
Braunschweig, 
Golub, et al., 
2012) 
Plasma Mothers of 
children w/ 
autistic disorder  
ADOS, 
AD-IR, 
DSM-IV-
TR, ICD-
10, 
MSEL, 
VABS, 
ABC 
Mothers w/ 
typically 
developing 
children or 
children w/ 
non-autism 
DD (MSEL, 
VABS, SCQ, 
ABC) 
- 
(Goines et al., 
2011) 
Plasma Mothers of 
children w/ 
autistic disorder 
or ASD 
ADOS, 
ADI-R, 
ABC, 
MSEL, 
VABS, 
DSM-IV/ 
ICD-10 
Mothers of 
typically 
developing 
children 
(MSEL, 
VABS, ABC, 
SCQ)  
Age-matched 
children  
(Heuer et al., 
2011) 
Plasma Mothers w/ ASD 
children 
ADI-R, 
DSM-IV/ 
ICD-10, 
ADOS 
modules 1 
or 2  
Mothers of 
children w/out 
ASD (did not 
meet ASD 
criteria, 
SCQ).  
--- 
(Singer et al., 
2009) 
Serum Mothers of 
children w/ 
autistic disorder 
and moderately 
to severely 
impaired in 
adaptive and 
cognitive ability, 
(excluded PDD-
NOS, Asperger’s 
Disorder, autism 
w/ known 
genetic/ 
metabolic 
etiologies  
DSM-IV, 
ADOS or 
CARS, IQ 
 
Mothers w/ 
unaffected 
children  
-Collected 
information on 
maternal age at 
pregnancy 
(Croen et al., 
2008) 
Plasma Mothers w/ ASD 
children (early 
onset or 
regression)  
DSM-IV Mothers w/ 
typically 
developing 
children or 
-Prenatal and 
neonatal 
maternal blood 
samples 
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children w/ 
MR  
(Martin et al., 
2008) 
Serum Mothers of at 
least one autistic 
kid and one ASD 
kid 
 
Autism 
Genetic 
Resource 
Exchange 
Mothers w/ 
typically 
developing 
children 
- 
(Singer et al., 
2008) 
Serum Mothers of 
autistic children 
w/ moderate-
severe 
impairments in 
adaptive and 
cognitive ability 
(excluded 
Asperger’s 
Disorder, PDD-
NOS, autism w/ 
known genetic/ 
metabolic 
etiologies 
DSM-IV, 
ADOS-G 
or CARS, 
IQ 
Mothers of 
unaffected 
children w/ no 
autism (no 
history of 
DSM-IV in 
the mother, 
her other 
children, or 
first-degree 
family 
members) 
 
-Collected 
information on 
familial 
history of 
autoimmune 
conditions and 
info on 
pregnancies  
-Age-matched 
mothers  
(Braunschweig 
et al., 2008) 
Plasma Mothers of 
children with 
autism w/ early 
onset or children 
w/ autism w/ 
regression 
ADI-R, 
ADOS 
modules 1 
or 2,  
ICD-10/ 
DSM-IV, 
SCQ, 
MSEL 
Mothers w/ 
typically 
developing 
children or 
DD children 
who did not 
meet ADOS 
and ADI-R 
cutoff criteria, 
also used 
MSEL, VABS 
Matched 
maternal age 
and children 
age 
(Zimmerman et 
al., 2007) 
Serum Mothers of LFA 
or HFA children. 
Some mothers 
w/ autoimmune 
conditions (e.g. 
rheumatoid 
arthritis, SLE). 
While pregnant, 
some mothers 
had taken 
medications 
known to affect 
VABS, 
IQ, DSM-
IV, CARS 
Healthy 
mothers of 
typically 
developing 
children. No 
family history 
of DD, on no 
medications, 
no immune-
related 
conditions  
- 
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the immune 
system (e.g. 
azathioprine, 
prednisone). 
Some children 
had regression or 
epilepsy, none 
w/ 
immunological 
disease or drug 
history 
(Dalton et al., 
2003) 
Serum Mother w/ 3 
children: normal 
boy (oldest), girl 
w/ high-
functioning 
ASD, and a boy 
w/ language 
regression 
(youngest) 
 
 
 
Clinical 
diagnosis 
by 
pediatric 
experts  
 
Women w/ 1-
4 normal 
children  
No history of 
autoimmune 
conditions. 
two extended 
family 
members w/ 
ASD, 4 of the 
children’s 
cousins 
(mothers side) 
have speech 
delay issues.  
(Warren et al., 
1990) 
Serum Mothers of 
children 
diagnosed w/ 
infantile autism 
DSM-III, 
Autism 
Behavior 
Checklist, 
IQ 
N/A - 
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